Phase II
Aridis’ COVID-19 therapy is particularly exciting. AR-711 is an inhaled, self-administered, at-home treatment for mild-to-moderate SARS-CoV-2 infections.
Constellation Pharmaceuticals announced on Sunday that it has received preliminary data from its Phase II MANIFEST and Phase III MANIFEST-2 clinical trials involving CPI-0610 for myelofibrosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
With 36 Janssen-sponsored studies and another nearly 50, it has supported, the Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, December 5-8.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
MediciNova announced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects.
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
PRESS RELEASES